- call +1-201-465-4211
- email sales@mrinsights.biz
Adoption of innovative technologies in screening & diagnostic tests is projected to drive growth. The incorporation of multiparametric MRI (mp-MRI) can significantly improve the detection of tumor and also provide confirmation whether there is a need for tissue biopsy. In addition, market players are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, there is a strong pipeline of products such as Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer), ODM-201 (Orion and Bayer), which are in their phase 3 studies and are projected to enter the market in the near future. In addition, many generic products are likely to enter the market owing to the expiry of patents of the major existing products during the forecast period. Thus, these factors are expected to drive growth.
Scope of the Report:
Asia Pacific is anticipated to be the fastest growing market over the forecast period. Rising awareness of such tumors would primarily drive growth. Governments of various countries in this region are playing a vital role in creating awareness through programs and online portals that provide detailed information regarding screening & diagnosis through PSA blood tests and DRE for male patients over 50 years of age.
The global Prostate Cancer Treatment Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Prostate Cancer Treatment Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Prostate Cancer Treatment Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Prostate Cancer Treatment Drugs market by product type and applications/end industries.
Market Segment by Companies, this report covers
Johnson & Johnson
Astella
Sanofi
Ipsen
Bayer
AstraZeneca
Dendreon
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Zytiga
Gonax
Lupron
Zoladex
Decapeptyl
Eligard
Vantas
Casodex
Others
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Prostate Cancer Treatment Drugs Market Overview
1.1 Product Overview and Scope of Prostate Cancer Treatment Drugs
1.2 Classification of Prostate Cancer Treatment Drugs by Types
1.2.1 Global Prostate Cancer Treatment Drugs Revenue Comparison by Types (2017-2023)
1.2.2 Global Prostate Cancer Treatment Drugs Revenue Market Share by Types in 2017
1.2.3 Zytiga
1.2.4 Gonax
1.2.5 Lupron
1.2.6 Zoladex
1.2.7 Decapeptyl
1.2.8 Eligard
1.2.9 Vantas
1.2.10 Casodex
1.2.11 Others
1.3 Global Prostate Cancer Treatment Drugs Market by Application
1.3.1 Global Prostate Cancer Treatment Drugs Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.4 Global Prostate Cancer Treatment Drugs Market by Regions
1.4.1 Global Prostate Cancer Treatment Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Prostate Cancer Treatment Drugs Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Prostate Cancer Treatment Drugs Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Prostate Cancer Treatment Drugs Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Prostate Cancer Treatment Drugs Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Prostate Cancer Treatment Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of Prostate Cancer Treatment Drugs (2013-2023)
2 Manufacturers Profiles
2.1 Johnson & Johnson
2.1.1 Business Overview
2.1.2 Prostate Cancer Treatment Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Johnson & Johnson Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 Astella
2.2.1 Business Overview
2.2.2 Prostate Cancer Treatment Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Astella Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sanofi
2.3.1 Business Overview
2.3.2 Prostate Cancer Treatment Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sanofi Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Ipsen
2.4.1 Business Overview
2.4.2 Prostate Cancer Treatment Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Ipsen Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bayer
2.5.1 Business Overview
2.5.2 Prostate Cancer Treatment Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bayer Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.6 AstraZeneca
2.6.1 Business Overview
2.6.2 Prostate Cancer Treatment Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 AstraZeneca Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.7 Dendreon
2.7.1 Business Overview
2.7.2 Prostate Cancer Treatment Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Dendreon Prostate Cancer Treatment Drugs Revenue, Gross Margin and Market Share (2016-2017)
3 Global Prostate Cancer Treatment Drugs Market Competition, by Players
3.1 Global Prostate Cancer Treatment Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Prostate Cancer Treatment Drugs Players Market Share
3.2.2 Top 10 Prostate Cancer Treatment Drugs Players Market Share
3.3 Market Competition Trend
4 Global Prostate Cancer Treatment Drugs Market Size by Regions
4.1 Global Prostate Cancer Treatment Drugs Revenue and Market Share by Regions
4.2 North America Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
4.5 South America Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
5 North America Prostate Cancer Treatment Drugs Revenue by Countries
5.1 North America Prostate Cancer Treatment Drugs Revenue by Countries (2013-2018)
5.2 USA Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
6 Europe Prostate Cancer Treatment Drugs Revenue by Countries
6.1 Europe Prostate Cancer Treatment Drugs Revenue by Countries (2013-2018)
6.2 Germany Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
6.3 UK Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
6.4 France Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Prostate Cancer Treatment Drugs Revenue by Countries
7.1 Asia-Pacific Prostate Cancer Treatment Drugs Revenue by Countries (2013-2018)
7.2 China Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
7.5 India Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
8 South America Prostate Cancer Treatment Drugs Revenue by Countries
8.1 South America Prostate Cancer Treatment Drugs Revenue by Countries (2013-2018)
8.2 Brazil Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Prostate Cancer Treatment Drugs by Countries
9.1 Middle East and Africa Prostate Cancer Treatment Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa Prostate Cancer Treatment Drugs Revenue and Growth Rate (2013-2018)
10 Global Prostate Cancer Treatment Drugs Market Segment by Type
10.1 Global Prostate Cancer Treatment Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global Prostate Cancer Treatment Drugs Market Forecast by Type (2018-2023)
10.3 Zytiga Revenue Growth Rate (2013-2023)
10.4 Gonax Revenue Growth Rate (2013-2023)
10.5 Lupron Revenue Growth Rate (2013-2023)
10.6 Zoladex Revenue Growth Rate (2013-2023)
10.7 Decapeptyl Revenue Growth Rate (2013-2023)
10.8 Eligard Revenue Growth Rate (2013-2023)
10.9 Vantas Revenue Growth Rate (2013-2023)
10.10 Casodex Revenue Growth Rate (2013-2023)
10.11 Others Revenue Growth Rate (2013-2023)
11 Global Prostate Cancer Treatment Drugs Market Segment by Application
11.1 Global Prostate Cancer Treatment Drugs Revenue Market Share by Application (2013-2018)
11.2 Prostate Cancer Treatment Drugs Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
12 Global Prostate Cancer Treatment Drugs Market Size Forecast (2018-2023)
12.1 Global Prostate Cancer Treatment Drugs Market Size Forecast (2018-2023)
12.2 Global Prostate Cancer Treatment Drugs Market Forecast by Regions (2018-2023)
12.3 North America Prostate Cancer Treatment Drugs Revenue Market Forecast (2018-2023)
12.4 Europe Prostate Cancer Treatment Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Prostate Cancer Treatment Drugs Revenue Market Forecast (2018-2023)
12.6 South America Prostate Cancer Treatment Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Prostate Cancer Treatment Drugs Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Prostate Cancer Treatment Drugs Picture
Table Product Specifications of Prostate Cancer Treatment Drugs
Table Global Prostate Cancer Treatment Drugs and Revenue (Mil
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
